Becton, Dickinson and Company (BDX)
NYSE: BDX · Real-Time Price · USD
182.69
-0.89 (-0.48%)
Aug 13, 2026, 2:52 PM EDT - Market open
BDX Financials Overview
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Revenue Revenue Growth | 20,840 | 21,840 | 20,178 | 19,372 | 18,870 | 19,131 |
Revenue Growth | 5.19% | 8.24% | 4.16% | 2.66% | -1.36% | 19.02% |
Gross Profit Gross Profit Growth | 9,679 | 9,925 | 9,125 | 8,170 | 8,477 | 8,631 |
Operating Income Operating Income Growth | 2,005 | 2,579 | 2,397 | 2,111 | 2,282 | 2,250 |
Net Income Net Income Growth | 941 | 1,678 | 1,705 | 1,424 | 1,689 | 2,002 |
Earnings Per Share EPS Growth | 3.32 | 5.82 | 5.86 | 4.94 | 5.88 | 6.85 |
EPS Growth | -39.53% | -0.68% | 18.62% | -15.99% | -14.16% | 152.77% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Medication Delivery Solutions Medication Delivery Solutions Growth | 4,657 | 4,575 | 4,429 | 4,293 | 4,308 | 4,101 |
Specimen Management Specimen Management Growth | 1,946 | 1,871 | 1,833 | - | - | - |
Medication Management Solutions Medication Management Solutions Growth | 3,553 | 3,474 | 3,297 | 2,980 | 2,533 | 2,432 |
Advanced Patient Monitoring Advanced Patient Monitoring Growth | 1,174 | 1,082 | 74 | - | - | - |
BioPharma Systems BioPharma Systems Growth | 2,391 | 2,324 | 2,273 | 2,229 | 2,001 | 1,828 |
Peripheral Intervention Peripheral Intervention Growth | 2,082 | 1,996 | 1,933 | 1,865 | 1,759 | 1,711 |
Urology and Critical Care Urology and Critical Care Growth | 1,734 | 1,649 | 1,554 | 1,374 | 1,305 | 1,232 |
Surgery Surgery Growth | 1,651 | 1,572 | 1,492 | 1,497 | 1,400 | 1,296 |
Diagnostic Solutions Diagnostic Solutions Growth | - | 1,838 | 1,846 | - | - | - |
Biosciences Biosciences Growth | - | 1,458 | 1,512 | 1,509 | 1,379 | 1,305 |
Revenue (Total) Revenue (Total) Growth | 20,840 | 21,840 | 20,178 | 19,372 | 18,870 | 19,131 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Investments Cash & Investments Growth | 709 | 649 | 2,162 | 1,424 | 1,014 | 2,295 |
Total Debt Total Debt Growth | 16,808 | 19,181 | 20,110 | 15,879 | 16,065 | 17,610 |
Net Cash (Debt) Net Cash Growth | -16,099 | -18,532 | -17,948 | -14,455 | -15,051 | -15,315 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -57.05 | -64.23 | -61.68 | -50.12 | -52.38 | -52.43 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 1,919 | 3,430 | 3,798 | 2,989 | 2,634 | 4,647 |
Capital Expenditures CapEx Growth | -728 | -760 | -725 | -874 | -973 | -1,194 |
Free Cash Flow Free Cash Flow Growth | 1,191 | 2,670 | 3,073 | 2,115 | 1,661 | 3,453 |
Free Cash Flow Growth | -61.91% | -13.11% | 45.30% | 27.33% | -51.90% | 24.66% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Gross Margin | 46.44% | 45.44% | 45.22% | 42.17% | 44.92% | 45.12% |
Operating Margin | 9.62% | 11.81% | 11.88% | 10.90% | 12.09% | 11.76% |
Pretax Margin | 7.40% | 8.61% | 9.94% | 8.58% | 9.45% | 8.84% |
Profit Margin | 4.52% | 7.68% | 8.45% | 7.90% | 8.66% | 8.38% |
FCF Margin | 5.71% | 12.23% | 15.23% | 10.92% | 8.80% | 18.05% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 13, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Dividend Per Share Dividend Per Share Growth | 4.200 | 4.160 | 3.800 | 3.640 | 3.480 | 3.320 |
Dividend Per Share Growth | 0.96% | 9.47% | 4.40% | 4.60% | 4.82% | 5.06% |
Dividend Yield | 2.30% | 2.22% | 1.57% | 1.51% | 1.70% | 1.51% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 13, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
PE Ratio | 31.52 | 32.16 | 41.14 | 52.33 | 37.90 | 34.99 |
Forward PE | 13.85 | 12.94 | 17.29 | 19.65 | 19.05 | 21.64 |
P/FCF Ratio | 19.35 | 20.01 | 22.68 | 35.50 | 38.01 | 19.74 |
PS Ratio | 2.23 | 2.45 | 3.45 | 3.88 | 3.35 | 3.56 |